EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy-Reference-Cited by-全球学者库

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Published:2004-06-04 Issue:5676 Volume:304 Page:1497-1500
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Paez J. Guillermo¹²³⁴⁵,Jänne Pasi A.¹²³⁴⁵,Lee Jeffrey C.¹²³⁴⁵,Tracy Sean¹²³⁴⁵,Greulich Heidi¹²³⁴⁵,Gabriel Stacey¹²³⁴⁵,Herman Paula¹²³⁴⁵,Kaye Frederic J.¹²³⁴⁵,Lindeman Neal¹²³⁴⁵,Boggon Titus J.¹²³⁴⁵,Naoki Katsuhiko¹²³⁴⁵,Sasaki Hidefumi¹²³⁴⁵,Fujii Yoshitaka¹²³⁴⁵,Eck Michael J.¹²³⁴⁵,Sellers William R.¹²³⁴⁵,Johnson Bruce E.¹²³⁴⁵,Meyerson Matthew¹²³⁴⁵

Affiliation:

1. Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

2. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

3. Departments of Pathology and Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

4. The Broad Institute at MIT and Harvard, Cambridge, MA 02142, USA.

5. Genetics Branch, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889, USA.

Abstract

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference29 articles.

1. Opportunities and challenges in the development of kinase inhibitor therapy for cancer

2. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

3. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

5. Mutations of the BRAF gene in human cancer

Cited by 8377 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics;Talanta;2024-03

2. Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives;The Journal of Liquid Biopsy;2024-03

3. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02

4. Synthesis and Anticancer Evaluation of Lawsone bound triazoles;ChemistrySelect;2024-02-02

5. Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells;Chinese Chemical Letters;2024-02